Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
- Risk-stratification following acute coronary syndromes using a novel electrocardiographic technique to measure variability in morphology.Comput Cardiol. 2008; (forthcoming)
- Safety, tolerability, and initial efficacy of AZD6140, the first reversible oral adenosine diphosphate receptor antagonist, compared with clopidogrel, in patients with non-ST-segment elevation acute coronary syndrome.J Am Coll Cardiol. 2007; 50: 1844-1851
- Automatic classification of heartbeats using ECG morphology and heartbeat interval features.IEEE Trans Biom Eng. 2004; 51;: 1196-1206
- Denoising by soft-thresholding.IEEE Trans Inf Theory. 2005; 41: 613-627
- Robust heart rate estimate fusion using signal quality indices and a Kalman filter.Physiol Meas. 2008; 29: 15-32
- Considerations in dynamic time-warping algorithms for discrete word recognition.IEEE Trans Sig Proc. 1978; 26: 575-582
- Introduction to Algorithms.2nd ed. MIT Press and McGraw Hill, 2001
- Heart rate variability: standards of measurement, physiological interpretation, and clinical use: Task Force of the European Society of Cardiology the North American Society of Pacing Electrophysiology.Circulation. 1996; 93: 1043-1065
- Risk stratification and therapeutic decision-making in acute coronary syndromes.JAMA. 2000; 284: 876-878
- Spatial, temporal and wavefront direction characteristics of 12-lead T-wave morphology.Med Biol Eng Comput. 1999; 37: 574-584
- Analysis of 12-lead T-wave morphology for risk stratification after myocardial infarction.Circulation. 2000; 102: 1252-1257
This work was supported, in part, by Center for Integration of Medicine and Innovative Technology, Harvard-MIT Division of Health Sciences and Technology, and Industrial Technology Research Institute (Taiwan). The DISPERSE2 trial was supported by AstraZeneca.